Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

BACKGROUND: Sunitinib and pazopanib are extensively used as first-line treatment of metastatic renal cell carcinoma (mRCC). We performed this meta-analysis to assess the anti-tumor effectiveness, toxicity, and total costs of the two drugs among patients with mRCC/advanced RCC (aRCC). Materials and M...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Huan, Huang, Yu, Hong, Zhengdong, Yuan, Xuhui, Cao, Zhi, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533682/
https://www.ncbi.nlm.nih.gov/pubmed/31122210
http://dx.doi.org/10.1186/s12885-019-5704-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533682/
https://www.ncbi.nlm.nih.gov/pubmed/31122210
http://dx.doi.org/10.1186/s12885-019-5704-3

Ejemplares similares